Harkerbio
Chief Innovation Officer
Harkerbio
Vice President Discovery Research
Harkerbio May 2017 - Jul 2017
Scientific Advisory Board Member
Boehringer Ingelheim Oct 1, 2009 - Feb 2017
Senior Principal Scientist
Delphine Collin Oct 1, 2009 - Feb 2017
Founder and President
Education:
Paris - Sud University (Paris Xi) 1995 - 1999
Doctorates, Doctor of Philosophy, Chemistry
Paris - Sud University (Paris Xi) 1989 - 1995
Doctorates
Skills:
Biophysics Drug Discovery Protein Chemistry Assay Development High Throughput Screening Life Sciences Medicinal Chemistry Nmr Drug Design Drug Development Laboratory Automation Screening Project Portfolio Management Biochemistry Lean Six Sigma Pharmaceutical Industry Project Leadership Spr Biotechnology Immunology
Orange Business Services
Technical Solutions Expert
The Chichester Biltong Company Jun 2012 - Aug 2012
Commercial Assistant
Orange Jun 2012 - Aug 2012
Expert Solutions Techniques
Education:
Lycée Robert Schuman 2011 - 2013
Lycée Robert Scumann, Metz 2011 - 2013
Skills:
Networking Telecommunications Internet Protocol Integration Voice Over Ip Cisco Technologies One Access Ansible Docker Vmware Esx Puppet Nagios Python Html Feuilles De Style En Cascade Sql Ruby Quality of Service Border Gateway Protocol Acl Php Git C Java Json Microsoft Office Linux Javascript Mobile Devices Network Administration
- Ingelheim am Rhein, DE Steven Richard BRUNETTE - New Milford CT, US Delphine COLLIN - New Milford CT, US Robert Owen HUGHES - Newtown CT, US Xiang LI - New Milford CT, US Shuang LIANG - Roseville MN, US Robert SIBLEY - North Haven CT, US Michael Robert TURNER - Danbury CT, US Lifen WU - New Milford CT, US Qiang ZHANG - Ridgefield CT, US
International Classification:
C07D 475/00 C07D 487/04 C07D 475/10 A61K 31/33
Abstract:
The present invention encompasses compounds of the formula (I)wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
- Ingelheim am Rhein, DE Steven Richard BRUNETTE - New Milford CT, US Delphine COLLIN - New Milford CT, US Robert Owen HUGHES - Newtown CT, US Xiang LI - New Milford CT, US Shuang LIANG - Roseville MN, US Robert SIBLEY - North Haven CT, US Michael Robert TURNER - Danbury CT, US Lifen WU - New Milford CT, US Qiang ZHANG - Ridgefield CT, US
International Classification:
C07D 475/00
Abstract:
The present invention encompasses compounds of the formula (I)wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
- Ingelheim am Rhein, DE Steven Richard BRUNETTE - New Milford CT, US Delphine COLLIN - New Milford CT, US Robert Owen HUGHES - Newtown CT, US Xiang LI - New Milford CT, US Shuang LIANG - Roseville MN, US Robert SIBLEY - North Haven CT, US Michael Robert TURNER - Danbury CT, US Lifen WU - New Milford CT, US Qiang ZHANG - Ridgefield CT, US
International Classification:
C07D 475/00
Abstract:
The present invention encompasses compounds of the formula (I)wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
- Ingelheim am Rhein, DE Steven Richard BRUNETTE - New Milford CT, US Delphine COLLIN - New Milford CT, US Robert Owen HUGHES - Newtown CT, US Xiang LI - New Milford CT, US Shuang LIANG - Roseville MN, US Robert SIBLEY - North Haven CT, US Michael Robert TURNER - Danbury CT, US Lifen WU - New Milford CT, US Qiang ZHANG - Ridgefield CT, US
International Classification:
C07D 487/04
Abstract:
The present invention encompasses compounds of the formula (I)wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.